Gilead provides peek at HCV discount, starts dividend program
Gilead Sciences Inc. (NASDAQ:GILD) projected that its HCV drugs will see a U.S. blended rebate of about 46% in 2015 and announced the start of a dividend program. The announcements came as the company announced 2014 earnings and gave FY15 sales guidance of $26-$27 billion, which is shy of the Street's $28 billion consensus estimate.
Gilead's EVP of Commercial Operations Paul Carter said on a conference call that the 2015 gross to net adjustment for Sovaldi sofosbuvir and Harvoni ledipasvir/sofosbuvir will be more than double the 22% the company reported in 2014. Carter said the increase reflects a shift towards a higher proportion of public payers such as Medicaid and the U.S. Department of Veterans Affairs, which he said will receive rebates in excess of 50%. ...